Table 3.
Identified microorganisms and administered antibiotics
| Causative organism | 1st line antibiotics | 2nd line antibiotics | N | % |
|---|---|---|---|---|
| MRSA | Vancomycin ± Ripamfin | Teicoplanin or Linezolid ± Ripamfin | 9 | 20 |
| MSSA | Nafcillin | Cefazolin | 7 | 15.6 |
| MRSE | Vancomycin | Teicoplanin or Linezolid | 4 | 8.9 |
| Streptococcus agalactiae (group B) | Penicillin | Cefazolin | 4 | 8.9 |
| E. coli | Cefotaxime → Ciprofloxacin(PO) | Piperacillin/Tazobactam → Ciprofloxacin(PO) | 3 | 6.7 |
| Streptococcus viridans | Penicillin | N | 2 | 4.4 |
| Klebsiella pneumoniae | Cefotaxime → Ciprofloxacin(PO) | N | 1 | 2.2 |
| Enterobacter cloacae | Cefotaxime + Amikacin | N | 1 | 2.2 |
| Acinetobacter baumannii | Ceftazidime → Piperacillin/Tazobactam | N | 1 | 2.2 |
| Beta-Streptococcus, Group C Streptococcus, MSSA | Ampicillin/sulbactam → Cefazolin | N | 1 | 2.2 |
| Bacillus species, MRSE, Enterotoccocus faecalis (group D) | Vancomycin + Fluconazole | N | 1 | 2.2 |
| Unidentified | Cefazolin ± Ripamfin, Vancomycin ± Ripamfin | N | 11 | 24.4 |
| 45 | 100 |
MRSA methicillin-resistant Staphylococcus aureus, MSSA methicillin-sensitive Staphylococcus aureus, MRSE methicillin-resistant Staphylococcus epidermidis, PO per os (Change IV antibiotics with PO antibiotics)